Company Initiates Pivotal Study for Epinephrine Nasal Powder, Targets 2027 NDA Filing
1 report, 1 independent
Updated Oct 6
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Belhaven Biopharma, Inc. announced the initiation of a pivotal clinical study evaluating BBP01, an investigational nasal powder formulation of epinephrine. The randomized, open-label, three-treatment crossover study compares BBP01 against established intramuscular epinephrine auto-injectors and manual injections. The company stated this study will generate the definitive data needed for a pre-NDA meeting with the FDA in the first quarter of 2027.
From finanznachrichten.de
Why it matters
The successful completion of the study and subsequent FDA review could pave the way for a New Drug Application filing in 2027. The product is being developed as a needle-free alternative for the delivery of epinephrine to treat anaphylaxis.
From finanznachrichten.de
Who's involved
- FDARecipient of the definitive data for the potential New Drug Application
Keep exploring
The entities involved
Related events
- FDA approval supports NDA submission in Aurora.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- BridgeBio announced on August 14, 2026, that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA).